// App-Quantinova.ai

P6-04-15 : Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Researchers

Presenter

  • Mandy Lawson

Principal Investigators

  • Natalie Cureton

  • Oona Delpuech

  • Pei Zhang

  • Azadeh Cheraghchi-Bashi-Astaneh

  • Sladjana Gagrica

  • Dawn Trueman

  • Gareth Maglennon

  • Daniel Sutton

  • Bairu Zhang

  • Jonathan Cairns

  • Teresa Klinowska

  • Christopher J Morrow

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

  • Breast cancer

Biomarkers

  • Estrogen Receptor 1

Drug/Treatment

  • Fulvestrant

  • Alora

  • Tamoxifen

  • AZD-9496

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved